Targeting miR-133-3p via mesenchymal stem cells-derived exosomes as a novel cell-free therapy for testosterone-induced benign prostatic hyperplasia
{{output}}
Benign prostatic hyperplasia (BPH), the leading cause of lower urinary tract symptoms (LUTS), is commonly treated with conventional therapies that often have undesirable side effects. Safer alternatives such as bone marrow mesenchymal stem cells (BM-MSCs)-deri... ...
